A phase 2, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of three doses of TAK-128 in subjects with mild to moderate diabetic peripheral neuropathy.

Trial Profile

A phase 2, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of three doses of TAK-128 in subjects with mild to moderate diabetic peripheral neuropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs TAK 128 (Primary)
  • Indications Diabetic neuropathies
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 18 Dec 2008 Takeda Global Research & Development Center added as trial sponsor and affiliate as reported by Clinicaltrials.gov.
    • 11 Sep 2008 Actual patient number (343) added as reported by ClinicalTrials.gov.
    • 11 Sep 2008 Actual end date changed from 1 Feb 2007 to 1 May 2006 as reported by Clinicaltrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top